Biotechnology · Philadelphia, Pennsylvania, United States
$2.25
-2.60% (-$0.06)2026-07-10
Smart-Money SignalDistribution · 42/100— Insiders are net sellers over 90 days (-$117K, 9 sales vs 1 buy)
Revenue$0
Net Income-$19.2M
EPS$-0.14
Market Cap$404.4M
Price Performance
Historical data including institutional events
Company Profile
B
Brent Pfeiffenberger
CEO & Executive Director
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.
Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases.
Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
